Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 2 1

Status

Completed 5 Terminated 4 Withdrawn 2 Active not recruiting 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 270 Oxaliplatin 195 Carboplatin 191 Capecitabine 184 Docetaxel 178 apatinib 164 Paclitaxel 163 Bevacizumab 159 Gemcitabine 156 Radiotherapy 147 camrelizumab 146 Fluorouracil 144 Cyclophosphamide 126 Irinotecan 120 Drug Therapy 120 sintilimab 108 Etoposide 99 anlotinib 90 S 1 (combination) 89 pembrolizumab 86 Leucovorin 86 toripalimab 78 Pemetrexed 78 Doxorubicin 77 tislelizumab 76 Dexamethasone 71 Trastuzumab 65 Neoadjuvant Therapy 65 Rituximab 62 Cetuximab 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × vistusertib × Clear all

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡